Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab in Chronic Immune Thrombocytopenia (ITP)
NCT01440361Phase 2Withdrawn
- Sponsor
- GSK
- Start
- Mar 2013
- Primary completion
- Apr 2015
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of belimumab in immune thrombocytopenia (ITP), sponsored by GSK. Planned start Mar 2013; status: withdrawn.
02
Drugs
belimumab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT01440361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01440361.